《艾意凯咨询（L.E.K.）：制药行业的ESG竞赛已经揭开序幕（英文版）（23页）.pdf》由会员分享，可在线阅读，更多相关《艾意凯咨询（L.E.K.）：制药行业的ESG竞赛已经揭开序幕（英文版）（23页）.pdf（23页珍藏版）》请在三个皮匠报告上搜索。

1、SPECIAL REPORTThe Race Is On:ESG in the Pharma Industry SPECIAL REPORT2“Pharmaceutical firms are on their ESG game.They get the notion of science-based targets.Theyunderstand the criticality of delivering on ESG.”Director of ESG,large pharma company,US3L.E.K.ConsultingSPECIAL REPORTThe Race Is On:ES

2、G in the Pharma IndustryContents1.Summary 42.Introduction 63.L.E.K.survey 74.Summary of results 95.Climate commitments heating up?126.Strategies for future-proofing 214L.E.K.ConsultingSPECIAL REPORTThe Race Is On:ESG in the Pharma IndustrySummaryPerformance on ESG(environmental,social and governance

3、)metrics is becoming an increasingly important consideration for stakeholders across the corporate ecosystem,and the pharmaceutical industry is no exception.Events like COP bring mainstream attention to the topic,increasing the importance of addressing these urgent issues.In this report we look at t

4、he ESG priorities of pharma companies and their relative maturity across the different dimensions of ESG,based on an L.E.K.survey of 49 pharma businesses.Our findings highlight the following:.4ESG is gaining momentum.According to a Bloomberg Research forecast,ESG assets will surpass$50 trillion by 2

5、025,and pharma is going beyond legal requirements to address ESG-related issues.1Pharma companies appear comparatively more mature on the social dimensions of ESG.This is no surprise given the industrys fundamental purpose of improving the health of society.With the importance of health equity comin

6、g to the forefront,the emphasis on social metrics is set to continue,with topics like access and affordability of key concern for pharma.In addition,complex and expensive treatments coming to market will mean patients and healthcare systems will need more support throughout the treatment journey.Lar